Skip to main content
. 2022 Nov 4;43(48):5047–5057. doi: 10.1093/eurheartj/ehac615

Figure 2.

Figure 2

Inter-individual variation in proprotein convertase subtilisin/kexin type 9 from baseline to Day 510 (intention-to-treat population). Panel (A) and (B) show the percentage and absolute change in PCSK9, respectively, from baseline to Day 510. The waterfall plot shown represents the change in PCSK9between two specified time points in individuals with measurements at both baseline and Day 510. Data are presented in the following order: patients with the greatest increase to patients with the greatest decrease for each parameter. Inclisiran, n = 98; placebo, n = 105. ITT, intention-to-treat; PCSK9, proprotein convertase subtilisin/kexin type 9.